Skip to main content

Table 4 Cox proportional hazard regression analysis of gender, age, histology, smoking status, EGFR mutation, WIF1 methylation and SFRP5 methylation for progression-free survival (PFS)

From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Variable P value Hazard ratio (95% CI)
Smoking Status 0.986 1.004
(smokers/nonsmokers)   (0.615-1.640)
Histology 0.689 0.915
(adenocarcinoma/Nonadenocarcinoma)   (0.592-1.414)
Gender 0.006 0.516
(male/female)   (0.322-0.826)
Age 0.456 0.858
(<65/>65)   (0.575-1.282)
Lines of Treatment 0.302 0.807
(first line/non-first line)   (0.537-1.213)
EGFR Mutation 0.024 0.656
(mutation/wide type)   (0.455-0.945)
SFRP5 Methylation 0.008 2.165
(methylated/unmethylated)   (1.226-3.823)
WIF1 Methylation 0.224 1.804
(methylated/unmethylated)   (0.697-4.674)